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The Spacehaler= (Evans Medical Ltd, Leatherhead, U.K.) is a new, compact, inhaler device containing the same
aerosol canister as a conventional metered dose inhaler (MDI). However, the design of the Spacehaler= has been
shown to reduce the velocity of the aerosol, thus reducing the proportion of non-respirable particles delivered to the
patient. This study compared radioaerosol deposition patterns following inhalation of 250 ìg of beclomethasone
dipropionate from the Spacehaler= and a conventional MDI (Beclazone=, Norton Health Care, Harlow, U.K.).
After rigorous in vitro validation of the radiolabelling technique, 12 asthmatic subjects (seven men aged 20–69
years, mean baseline FEV1 2·59 l (sd 0·55 l) received one dose of
99mTc-labelled beclomethasone dipropionate 250 ìg
via either a Spacehaler= or MDI on each of two study days in a randomized cross-over manner. All subjects had
been taught the required inhalation technique before the dose was administered. Inhalation details were recorded
using a spirometer connected in series with the device. Lung and oropharyngeal depositions were measured by
gamma scintigraphy.
The mean percentage of the metered dose deposited in the lungs was 23·0% (sd 8·3%) for the Spacehaler= and
12·8% (sd 6·8%) for the MDI (P<0·01). However, there was no significant diVerence in the distribution patterns
within the lungs between the two devices. Oropharyngeal deposition was significantly lower (P<0·01) for the
Spacehaler= than for the MDI [mean (sd) 27·9% (16·4%) and 73·6% (8·7%), respectively] whilst the percentage of the
metered dose remaining on the Spacehaler= actuator was significantly greater than that on the MDI actuator [mean
(sd) 48·0% (11·8%) and 12·4% (8·5%) respectively, P<0·01]. There was evidence from the inhalation recordings that
some patients experienced the ‘cold Freon eVect’ whilst using the metered dose inhaler which may have contributed
to the lower lung deposition seen with this device.
This study demonstrates that the proportion of a 250 ìg dose of beclomethasone dipropionate that is delivered to
the lungs is significantly greater with the Spacehaler= than the MDI. The Spacehaler= also reduces the proportion
of the does that is deposited in the oropharynx to less than half that observed with the MDI, and reduces the total
dose of drug received by the patient.
RESPIR. MED. (1999) 93, 424–431Received 12 January 1998 and accepted in revised form 9 March
1999.
Correspondence should be addressed to: Dr F. C. Upchurch,
Medeva Pharma Ltd, Medeva House, Kingston Rd, Leatherhead,
Surrey KT21 7PG, U.K.Introduction
The metered dose inhaler (MDI) has been the mainstay of
asthma management for the last 30 years. The concept of
delivering a small dose of drug directly to the airways is
logical, and the MDI is cheap and convenient (1). However,
there are some problems with MDI use. Firstly, the char-
acteristics of the aerosol mean that a dose of drug is emitted
from the MDI at high speed (typically 30 m s"1) contain-
ing a large proportion of particles that are more than 5 ìm
in diameter (2). Most of these particles (representing up to0954-6111/99/060424+08 $12.00/080% of the dose) impact on the oropharynx and are
swallowed (3) which may, particularly with inhaled corti-
costeroids, contribute to oral and systemic side-eVects.
Secondly, the devices are not easy to use. Many patients
have diYculty coordinating actuation and inhalation, and a
significant proportion are unable to continue to inhale
through the mouth when the aerosol is released into the
oropharynx (the ‘cold-Freon eVect’) (4).
A number of diVerent inhaler devices have been devel-
oped to overcome the problems of the MDI. Dry powder
inhalers may be relatively expensive and may not reduce
oropharyngeal deposition (5). Large volume spacer devices
reduce the velocity of the aerosol and the amount of drug
deposited in the oropharynx (6) but are bulky and cumber-
some. The Spacehaler= (Evans Medical Ltd, Leatherhead,
U.K.) (previously known as the Gentlehaler=) (7) is a new,
compact pressurized aerosol device that uses the same? 1999 W. B. SAUNDERS COMPANY LTD
IMPROVED TARGETING OF BDP WITH SPACEHALER= 425canister as a conventional metered dose inhaler. Its design
however, reduces the velocity of the aerosol cloud that
emerges from the inhaler from 30 to 2 m s"1 and retains
the majority of the non-respirable fraction of the emitted
dose (8). The Spacehaler= has been shown to produce
clinically equivalent bronchodilator eVects to a standard
MDI plus spacer when used to deliver 200 ìg salbutamol,
and to be preferred by patients (9).
Current U.K. guidelines on asthma management (10)
advise that patients receiving inhaled steroids via a MDI at
a dose of more than 800 ìg beclomethasone dipropionate
(BDP) or equivalent per day should use a large volume
spacer device in order to reduce the risk of local and
systemic eVects. However, there is little published work
comparing the deposition characteristics of BDP delivered
via the MDI with the large volume spacer in vivo. One study
has shown that use of a large volume spacer significantly
increased the percentage of a dose of BDP 250 ìg delivered
to the lungs compared with the MDI alone (11). The
current study has been performed in order to compare the
deposition of a single shot of BDP 250 ìg administered via
a Spacehaler= and conventional MDI in asthmatic
subjects.MethodsSPACEHALER= DEVICE
The Spacehaler= is a compact (7·5 cm long) low-velocity
pressurized aerosol device. It uses the same canister as a
conventional MDI, but incorporates a vortex chamber
immediately upstream of the nozzle, together with a narrow
air inlet in the rear and a bell-shaped internal surface in the
mouthpiece (Fig. 1). The eVect is to reduce the velocity of
the spray and to retain most of the non-respirable particles
within the actuator.SUBJECTS
Twelve non-smoking asthmatic subjects (seven men)
received study medication [age range 20–69 years; mean
baseline forced expiratory volume in 1 s (FEV1) 2·59 l (sd
0·55 l)]. A further two subjects entered the study but were
withdrawn before receiving treatment due to adverse events
(upper respiratory tract infection and acute exacerbation of
asthma). All subjects gave written informed consent. All
had a clinical diagnosis of asthma which had been con-
firmed by reversibility testing with an inhaled â-agonist.
They remained on their normal asthma medication
throughout the study. Each subject was only dosed on a
given study day providing their FEV1 was within 15% of its
value at the pre-study screen.STUDY DESIGN
This was a single centre, randomized, cross-over study.
Subjects who satisfied the entry criteria attended the centre
on two occasions, not less than 44 h apart. At each of these
visits they received a single dose of BDP (250 ìg perinhalation) delivered either via the Spacehaler= or a con-
ventional MDI, in a random order. The inhalation mode
was standardized for each dosage regimen and subjects
were taught the required technique using a placebo device.
Subjects were instructed to empty their lungs before taking
a slow deep inhalation. The investigator fired the device
approximately 1 s after the beginning of inhalation. At the
end of the inhalation a 10-s breath holding pause was
observed before the subject breathed out through a filter to
trap any radioactive aerosol in the expired air. During the
aerosol inhalations, the inhaled volume, inhaled flow rate
and breath holding pause were recorded by a Vitalograph
MDI-Compact spirometer connected in series with the
inhaler. The addition of this connector does not change the
particle size of the spray.
Deposition patterns in the lungs and oropharynx were
determined by gamma scintigraphy recorded immediately
following administration of the radiolabelled aerosol. Four
views were recorded: posterior chest; anterior chest; right
lateral oropharynx; and actuator/exhalation filter. Radio-
activity in the stomach and oesophagus was assumed to
have been deposited in the oropharynx. The amount of
radiolabel in the inhalers was adjusted so that the total
amount of radioactivity delivered did not exceed
10 MBq 99mTc per metered dose.
On one of the study days, unless they had previously
taken part in such an examination during the previous two
years, subjects underwent a posterior lung ventilation scan
using the inert gas 81mKr in order to determine the per-
imeter of the lung fields. On each study day lung function
measurements (FEV1, FVC and PEFR) were performed
before dosing and again at 30 min post-dosing. Approval
for the study was obtained from the Quorn Research
Review Committee and permission to administer the
radioactive aerosol from the Department of Health.RADIOLABELLING VALIDATION
Before comparing the in vivo lung deposition from the
Spacehaler= and pressurized MDI (Beclazone=, Norton
Health Care Ltd, Harlow, U.K.) it was first necessary to
develop and validate a radiolabelling method to ensure that
the radiolabel acted as an accurate marker of drug distri-
bution within the aerosol cloud. In vitro tests were carried
out using the High Precision Multi-stage Liquid Impinger
(HPMLI), which has an initial glass 90) bend (throat) and
four impaction stages. At a flow rate of 60 l min"1, par-
ticles between 3·1 and 6·8 ìm in diameter are collected in
stage 3 and particles with a diameter of less than 3·1 ìm are
collected in stage 4. Particles deposited in stages 3 and 4
therefore constitute the fine particle fraction.Determination of particle size of marketed BDP
MDIs delivering BDP 250 ìg per metered dose (Beclazone=,
Norton Health Care, Harlow, U.K.) were shaken in an
ultrasonic bath to mix the formulation thoroughly and then
primed by firing 10 shots to waste. These canisters were
designated ‘unlabelled MDIs’. The particle size distribution
426 S. P. NEWMAN ET AL.from these canisters was determined by firing the canister 40
times (shaken between each shot) into the HPMLI at a
continuous airflow of 60 l min"1. Each stage of the appar-
atus was washed out with methanol 50 ml and the washings
assayed using ultraviolet analysis to determine the concen-
tration of BDP in each solution. The percentage distribution
of BDP was calculated as the mass of drug recovered from
each stage of the HPMLI divided by the total mass of drug
recovered.Determination of particle size distribution of radiolabelled
BDP
MDIs were labelled using an adaptation of the method
described by Köhler et al. (12). MDIs containing radiolabel
(99mTc pertechnetate), BDP suspension and an additional
0·2 ml CFC-11 propellant were prepared using empty can-
isters and metering valves. These inhalers (designated
‘labelled MDIs’) were checked for leaks, and were mixed
and primed, before shots were fired into the HPMLI.
Washings from the HPLMI stages were taken and the
quantity of radiolabel in each stage was determined using a
gamma camera. The percentage distribution of drug was
also measured by ultraviolet analysis.
In addition, to ensure that process of manufacturing the
labelled MDIs did not aVect the particle size of the drug, a
further set of MDIs were prepared to the same method but
without the addition of radiolabel (‘CFC-added MDIs’).
The particle size distribution of these inhalers was measured
by ultraviolet analysis.DATA ANALYSIS
The lung outlines from the 81mKr ventilation scan were
used to define the perimeters of the lung fields on the
aerosol views. The lungs were divided into central,intermediate and peripheral regions of interest (13). The
peripheral lung zone/central lung zone deposition ratio
(lung penetration index) was calculated. Regions of interest
were also drawn around the oropharynx, oesophagus and
stomach. The counts obtained within these regions were
corrected for background radioactivity, radioactive decay
and tissue attenuation (14). In regions where both anterior
and posterior images were recorded, the geometric mean of
counts in both images was calculated. Determination of the
percentage of the dose deposited in the oropharynx
included activity adhering to the mouth and pharynx
together with any swallowed activity detected in the
oesophagus, stomach and intestine. The counts for each
area were expressed as a percentage of the metered dose,
which was determined from the sum of the total body
counts in addition to those deposited on the actuator and
the exhalation filter.STATISTICS
The Wilcoxon matched-pairs signed-ranks test was used
to determine whether diVerences between the deposition
patterns for the two devices were significant. A P-value of
ƒ0·05 was considered significant.ResultsTable 1. Validation of radiolabelling method. The percentage distribution of drug and radiolabel in ‘unlabelled’, ‘CFC-added’
and ‘labelled’ MDIs within a High Precision Multistage Liquid Impinger. Each data set shows mean and sd values for five
replicates
Unlabelled MDIs
Drug assay (UV)
CFC-added MDIs
Drug assay (UV)
Labelled MDIs
Drug assay (UV)
Labelled MDIs
Radiolabel assay
(gamma camera)
Mean (sd) Mean (sd) Mean (sd) Mean (sd)
Actuator (%) 8·1 (3·2) 9·4 (3·2) 10·5 (4·3) 7·3 (2·8)
Throat (%) 46·3 (5·2) 47·4 (5·9) 44·1 (4·9) 44·5 (3·6)
Stage 1 (%) 2·7 (1·4) 2·3 (0·9) 2·8 (1·0) 4·7 (1·3)
Stage 2 (%) 6·9 (1·7) 8·1 (1·0) 8·2 (1·3) 5·5 (1·0)
Stage 3 (%) 18·6 (3·2) 19·0 (2·5) 20·8 (0·8) 17·3 (1·9)
Stage 4 (%) 17·5 (1·6) 13·8 (2·1) 13·6 (3·1) 20·7 (4·5)
Fine particle fraction (%) 36·0 (4·4) 32·8 (4·4) 34·4 (2·8) 38·0 (3·5)
Recovered drug mass per dose (ìg) 246 (9) 265 (13) 259 (11)
Fine particle dose (ìg) 88 (10) 86 (9) 89 (10)VALIDATION OF RADIOLABELLING
TECHNIQUE
As can be seen from Table 1, this modified Köhler method
provides an acceptable means of radiolabelling BDP and
provides particle size data comparable with those from
unlabelled BDP inhalers. The ratio of the radiolabel fine
particle fraction to the fine particle fraction from the
unlabelled MDI was 1·06.
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Baseline lung function was similar on both study days:
mean baseline FEV1 was 2·66 l (sd 0·55 l) before the
Spacehaler= and 2·63 l (sd 0·54 l) before the MDI. In-
halation details for each subject are shown in Tables 2
and 3. Subject 4 failed to record an inhalation for the
Spacehaler= as a result of activating the spirometer whilst
sealing her lips around the device. Four subjects (numbers
4, 5, 10 and 14) paused during inhalation from the MDI
when the device was fired. All of the subjects continuedinhalation after this brief pause but the spirometer stopped
recording the inhalation at the time of the pause.Table 2. Inhalation details: Spacehaler=
Subject
No.
Duration of
inhalation (s)
Inhaled
volume (l)
Average inhalation
flow rate (l min"1)
Breath holding
pause (s)
01 6·6 3·59 32·6 11·3
04 NR NR NR NR
05 5·7 2·61 27·5 10·0
06 6·8 2·85 25·1 9·4
07 4·2 2·62 37·4 9·1
08 7·6 3·03 23·9 10·4
09 5·4 2·04 22·7 11·7
10 4·8 2·93 36·6 11·5
11 8·3 4·16 30·1 10·1
12 4·8 2·40 30·0 12·1
13 8·0 3·41 25·6 10·5
14 3·8 2·57 40·6 9·8
Mean 6·0 2·93 30·2 10·5
sd 1·6 0·60 6·0 1·0
n 11 11 11 11
NR, Not registered.Table 3. Inhalation details: MDI
Subject
No.
Duration of
inhalation (s)
Inhaled
volume (l)
Average inhalation
flow rate (l min"1)
Breath holding
pause (s)
01 6·8 3·26 28·8 12·7
04 NR NR NR NR
05 NR NR NR NR
06 4·1 2·75 40·2 10·5
07 5·3 3·13 35·4 9·9
08 8·4 2·48 17·7 10·4
09 4·2 2·00 28·6 12·6
10 NR NR NR NR
11 3·3 2·20 40·0 14·8
12 4·4 1·73 23·6 9·7
13 6·1 2·02 19·9 17·0
14 NR NR NR NR
Mean 5·3 2·45 29·3 12·2
sd 1·7 0·56 8·7 2·6
n 8 8 8 8
NR, Not registered.DEPOSITION PATTERNS
Deposition data for BDP delivered via the Spacehaler= and
the MDI are shown in Table 4. The mean (sd) whole lung
deposition was 23·0% (8·3%) and 12·8% (6·8%) for the
Spacehaler= and the MDI, respectively. Individual whole
lung deposition values are shown in Fig. 2. Whole lung
428 S. P. NEWMAN ET AL.deposition of BDP was significantly greater with the
Spacehaler= than the MDI (P<0·01).
There was a trend towards a lower mean peripheral/mean
central zone deposition ratio with the Spacehaler=
although this did not reach statistical significance.
Mean oropharyngeal deposition was significantly lower
for the Spacehaler= (27·9%) than the MDI (73·6%). A
significantly larger proportion of the metered dose was
deposited on the Spacehaler= than on the MDI (mean
values 48·0 and 12·4%). The mean percentage of the dose
captured on the exhalation filter for both the Spacehaler=
and the MDI was similar (1·1 and 1·2%, respectively).
Fig. 3 shows typical scintigraphic images obtained during
the study.SAFETY
Several subjects had small falls in FEV1 (<11% of baseline)
during the study days. Four subjects (numbers 1, 6, 9 and
13) experienced a fall in FEV1 after using both the Space-
haler= and the MDI. One subject (number 5) experienced a
fall in FEV1 only after using the Spacehaler
=. One serious
adverse event was reported during the study. Subject 7
experienced a fall in FEV1 of 29% 30 min after using the
MDI, which responded to bronchodilator treatment. Later
that day, the subject developed symptoms of an upper
respiratory tract infection and an acute exacerbation of
asthma, which was treated with a short course of oral
steroids and resolved without sequelae.Discussion
The radiolabelling method used in this study [modified
from the method described by Köhler et al. (12)] was
extensively validated in vitro before being used in vivo: the
validation process confirmed that the radiolabel did not
alter the particle size distribution of BDP and was an
accurate marker for the drug. The original method
described by Köhler et al. has been shown to alter theTable 4. Deposition data
Spacehaler=
(n=12)
MDI
(n=12)
Mean (sd) Mean (sd)
Whole lung (%) 23·00** (8·3) 12·8 (6·8)
Central lung (%) 8·6** (3·9) 4·5 (3·2)
Intermediate lung (%) 7·7** (2·6) 4·3 (2·6)
Peripheral lung (%) 6·7* (3·3) 4·1 (2·3)
Peripheral/central ratio 0·9 (0·4) 1·1 (0·4)
Oropharynx (%) 27·9** (16·4) 73·6 (8·7)
Actuator (%) 48·0** (11·8) 12·4 (8·5)
Exhalation filter (%) 1·1 (1·2) 1·2 (1·3)
*P<0·5; **P<0·01.characteristics of the aerosol in favour of large sized
particles compared with the unlabelled product (15). This
improvement on the original Köhler et al. method
described in this study represents a significant advance in
MDI radiolabelling strategies. The in vivo radionuclide
distributions measured by the gamma camera can therefore
be taken as a true reflection of the distribution of BDP both
in the body and on the devices used in the study.
The mean whole lung deposition for the MDI was 12·8%
of the metered dose, compared with 23·0% for the Space-
haler=. These results contrast with the findings of a pre-
vious scintigraphic study (8), which gave similar values for
whole lung depositions of salbutamol (100 ìg per actu-
ation) for the Spacehaler= and MDI (19·9 and 18·8%,
respectively). This discrepancy may arise from the way in
which patients in this study reacted to the fast and slow
moving sprays emerging from the MDI and Spacehaler=
respectively. Spray from the Spacehaler= travels at a vel-
ocity <2 m s"1. Patients may find it easier to inhale this
spray deeply into the lungs than the spray from the MDI
which travels at an initial velocity of <30 m s"1. In the
present study, lung deposition for the Spacehaler= was
close to the value seen in the previous study (8) while lung
deposition for the MDI was lower. Some of the discrepancy
may represent unusually poor performance with the
MDI.
Evidence from this study lends weight to this argument.
Despite a lengthy practice session immediately before dos-
ing, several subjects displayed a momentary pause in in-
halation just after actuation of the MDI, presumably as the
aerosol spray hit the back of the throat. This is the so-called
‘cold Freon’ eVect related to the cooling of the spray as
propellants evaporate, and also perhaps to the presence of
large particles (<10 ìm) emitted from the MDI. The eVect
was to stop the MDI Compact spirometer recording even
though the subject continued the inhalation. It is possible
that the problems the four subjects experienced in using the
MDI could have lowered the mean whole lung deposition
value for the whole group, although this does not appear to
have been the case. Of the four inhalations aVected in this
manner, two subjects had deposition values below the
average for the group, whilst two had deposition values
above the average for the group. The mean whole lung
deposition value for this sub-group was 13·6%, which was
similar to that obtained for the whole group (12·8%). In
addition, the values for mean whole lung deposition for the
eight subjects with perfect technique for both devices were
20·6% (sd 8·3%) for the Spacehaler= and 12·3% (sd 7·0%)
for the MDI; values which are very similar to those for the
full set of 12 subjects.
Two pharmacokinetic studies support the finding of
higher lung deposition for the Spacehaler= compared to the
MDI. One showed significantly higher levels plasma levels
of salbutamol in healthy volunteers during the first 60 min
after inhalation from an early prototype of the Spacehaler=
than from the MDI (16). Whether these subjects had any
problems using the MDI is not known, although it is our
experience that healthy volunteers who do not use MDI
regularly are more likely than asthmatic patients to exhibit
the cold-Freon eVect when inhaling from this device. A
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Fig. 2. Percentage whole lung deposition data for
Spacehaler= and MDI: individual patient plots.Fig. 3. Typical scintigraphic images obtained during the study.second study (17) showed increased urinary excretion
of mometasone furoate for an earlier prototype of the
Spacehaler= compared to the MDI, which was felt to
be due to enhanced lung deposition of drug from the
Spacehaler=.
Two other factors may help to explain the discrepancies
between the various studies carried out to evaluate the
Spacehaler=. First, diVerent drugs and doses were used in
the two studies (salbutamol 100 ìg and beclomethasone
250 ìg); diVerences in formulation (propellant mixtures,
propellant vapour pressures and plume geometries) make it
diYcult to extrapolate from one drug formulation to
another. However, the lower deposition value for the MDI
in the present study compared with that recorded in theprevious study (8) may reflect the higher dose of drug per
shot (250 ìg vs. 100 ìg). Previous scintigraphic data from
MDIs have shown that lung deposition decreases as the
mass of drug per metered dose increases (18,19). Second,
the Spacehalers= used in the two scintigraphic studies were
not identical; the device used in the present study had two
air inlet holes in the rear of the device, compared to only a
single hole for the earlier version of the device used in the
previous study. The single hole device had a very high
resistance to airflow and patients could only achieve an
average inhaled flow of 20 l min"1 with considerable
inspiratory eVort. In the present study, the resistance to
airflow was much less and patients could generate the
targeted inhaled flow of 30 l min"1 with ease. It may be
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with the device used in the present study, which could
explain why it performed better than the MDI. Further, the
air inlet holes probably perform an important function in
the formation of the low velocity cloud in the Spacehaler=
and it is possible that the spray kinetics of the Spacehaler=
devices used in the two scintigraphic studies diVered as a
consequence. Perhaps the slower aerosol stream from the
Spacehaler= optimizes lung deposition despite minor vari-
ations in inhaler technique which could adversely aVect the
performance of the standard MDI.
Oropharyngeal deposition for the Spacehaler= was sig-
nificantly lower than that for the MDI (27·9 and 73·6%,
respectively). The low oropharyngeal deposition with the
Spacehaler= is likely to be due to two factors: 1. the
function of the Spacehaler= mouthpiece is such that it has
drug delivery characteristics similar to those of a spacer,
with a significant fraction of the dose being retained on the
device itself; and 2. the relatively slow moving aerosol
cloud reduces the inertial mass of the larger particles and
enables a greater proportion of particles to remain
entrained within the inhaled airstream, thus reducing
impaction in the oropharynx. The diVerence in oropharyn-
geal deposition seen in this study is consistent with that
observed in the earlier scintigraphic study (8). The percent-
age of the dose in the exhaled air (i.e. trapped on the
exhalation filter) was very low for both the Spacehaler=
and the MDI, and was in line with the findings of previous
studies using MDIs (18). The distribution of radiolabel
within peripheral, intermediate and central lung zones
broadly resembled those observed in the previous
scintigraphic study with the Spacehaler= (8). The retention
of up to 48% of the dose on the device itself does not
appear to aVect performance: in vitro work has confirmed
that the deposition characteristics of the Spacehaler=
are consistent throughout the life of the inhaler. As a
hygiene precaution, patients are advised to wash the device
once a week.
In an ideal aerosol delivery system, drug delivery to the
lungs would account for 100% of the dose delivered to
the body with no drug being deposited in the oropharynx.
The Spacehaler= showed a considerable improvement in
lung deposition expressed as a percentage of total body
deposition (45·2%) when compared with the MDI (14·8%).
This performance is similar to that seen with a large volume
spacer device: in a study looking at lung deposition of BDP
250 ìg, a large volume spacer produced lung depo-
sition (expressed as a percentage of total body deposition)
of 48·7% compared with 17·4% for MDI alone (11). The
Spacehaler= targets drug to the lungs better than a conven-
tional MDI, and may be a suitable alternative to the large
volume spacer devices recommended in U.K. asthma
management guidelines for patients receiving high-dose
BDP (10).
On the basis of this study, the Spacehaler= represents an
improvement over conventional MDIs. It provides more
eYcient delivery of drug to the lungs, reduces the risk of
local and systemic side-eVects from oropharyngeal depo-
sition and results in a lower total dose of drug being
delivered to the patient.
IMPROVED TARGETING OF BDP WITH SPACEHALER= 43118. Newman SP. Therapeutic aerosol deposition in man.
In: Morén F, Dolovich MB, Newhouse MT, Newman
SP, eds. Aerosols in Medicine: Principles, Diagnosis and
Therapy. Amsterdam: Elsevier Science, 1993.19. Newman SP. Scintigraphic assessment of therapeutic
aerosols. Crit Rev Therapeut Drug Carrier Syst 1993;
10: 65–109.
